$PRME does cures better than $MRNA
$PRME$MRNA
AI SUMMARY — Post compares PRME's cure capabilities favorably to MRNA, though lacks detailed supporting evidence or clinical data. Key risks include unsubstantiated claims, biotech volatility, and clinical trial uncertainties.
| TICKER | PRME |
USER | u/Stonkgang_ |
| RATING |
BULLISH |
ENTRY |
$3.24
|
| POSITION |
1533 sh
SYN
|
BOOK VAL |
$4968.56 |
| CURRENT |
$3.26 |
P&L % |
+0.63%
|
| CURR VAL |
$5000.00 |
P&L $ |
+31.44
|
| TICKER | MRNA |
USER | u/Stonkgang_ |
| RATING |
BULLISH |
ENTRY |
$129.53
|
| POSITION |
37 sh
SYN
|
BOOK VAL |
$4894.38 |
| CURRENT |
$145.13 |
P&L % |
+12.05%
|
| CURR VAL |
$5484.05 |
P&L $ |
+589.67
|